{
  "docId": "019dd923-5f69-752d-a9b6-2758ff8024b8",
  "docSlug": "IOYPUci1JeH6qtF9hngI",
  "documentTitle": "See the 21-slide pitch deck a biotech startup used to convince investors like Pfizer to bet on fixing damaged organs",
  "authorId": "Pitchdecks",
  "authorName": "Agomab Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 19,
  "pageCount": 21,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram illustrates the signaling pathways (A, B, C) triggered by HGF/MET interaction, highlighting the selective activation of specific outcomes.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "flowchart"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-2758ff8024b8/19",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8#slide-19",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "AGMB-102 causes partial activation of MET: causing antifibrotic effect and cell survival, avoiding the proliferative effect.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-9d6a-7169-ab37-42e9b1d2ef40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "HGF/MET signaling pathway diagram showing proliferation, anti-fibrotic, and cell survival outcomes.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adaa0c04-b248-450f-85b2-5f2162d9b723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "Agomab selected series of MET binders with different epitopes compared to AGMB-101. AGMB-102 causes partial activation of MET: causing antifibrotic effect and cell survival, avoiding the proliferative effect. Intended for use in chronic indications. Currently in discovery stage.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb72bf8d-5543-4301-9b95-b8c32f2b631e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.12,
        "y": 0.08
      },
      "kind": "title",
      "text": "AGMB-102: partial MET agonist mAb for chronic diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91c3a422-0fd7-4e12-af92-8d02858e0d4b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "261cf333-aa91-4878-b5a2-569553101fd6",
      "evidence": "diagram/hub-spoke: HGF/MET signaling pathway diagram showing proliferation, anti-fibrotic, and cell survival outcomes",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}